Model Informed Drug Development Archives

Blog

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

CertaraMarch 3, 2026

Conference

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Danielle PillsburyMarch 2, 2026

Blog

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

CertaraFebruary 27, 2026

Blog

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

CertaraFebruary 26, 2026

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

– London, UK

CertaraFebruary 24, 2026

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle PillsburyFebruary 23, 2026

Blog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

CertaraFebruary 18, 2026

Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…

CertaraFebruary 13, 2026

Live Events

Certara IQ^™ Global Roadshow

Certara IQ™ is going on the road. From APAC to Europe to North America, our…

CertaraFebruary 12, 2026

Live Events

Certara IQ™ Workshop

CertaraFebruary 11, 2026

Model Informed Drug Development

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Certara IQ^™ Global Roadshow

Certara IQ™ Workshop

Newsletter sign up

Quick links

Solutions

Contact